Weiwei Feng1, Nan Jia2, Haining Jiao3, Jun Chen4, Yan Chen4, Yueru Zhang3, Menghan Zhu2, Chongying Zhu3, Lifei Shen3, Wenqing Long3. 1. Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin 2nd Road, Huangpu District, Shanghai, 200025, People's Republic of China. fww12066@rjh.com.cn. 2. Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 200091, People's Republic of China. 3. Department of Gynecology and Obstetrics, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, 197 Ruijin 2nd Road, Huangpu District, Shanghai, 200025, People's Republic of China. 4. Shanghai Gemple Biotech Co., Ltd., Shanghai, 201210, People's Republic of China.
Abstract
BACKGROUND: Currently, there is no reliable blood-based marker to track tumor recurrence in endometrial cancer (EC) patients. Liquid biopsies, specifically, circulating tumor DNA (ctDNA) analysis emerged as a way to monitor tumor metastasis. The objective of this study was to examine the feasibility of ctDNA in recurrence surveillance and prognostic evaluation of high-risk EC. METHODS: Tumor tissues from nine high-risk EC patients were collected during primary surgery and tumor DNA was subjected to next generation sequencing to obtain the initial mutation spectrum using a 78 cancer-associated gene panel. Baseline and serial post-operative plasma samples were collected and droplet digital PCR (ddPCR) assays for patient-specific mutations were developed to track the mutations in the ctDNA in serial plasma samples. Log-rank test was used to assess the association between detection of ctDNA before or after surgery and disease-free survival. RESULTS: Somatic mutations were identified in all of the cases. The most frequent mutated genes were PTEN, FAT4, ARID1A, TP53, ZFHX3, ATM, and FBXW7. For each patient, personalized ddPCR assays were designed for one-to-three high-frequent mutations. DdPCR analysis and tumor panel sequencing had a high level of agreement in the assessment of the mutant allele fractions in baseline tumor tissue DNA. CtDNA was detected in 67% (6 of 9) of baseline plasma samples, which was not predictive of disease-free survival (DFS). CtDNA was detected in serial post-operative plasma samples (ctDNA tracking) of 44% (4 of 9) of the patients, which predicted tumor relapse. The DFS was a median of 9 months (ctDNA detected) versus median DFS undefined (ctDNA not detected), with a hazard ratio of 17.43 (95% CI, 1.616-188.3). The sensitivity of post-operative ctDNA detection in estimating tumor relapse was 100% and specificity was 83.3%, which was superior to CA125 or HE4. CONCLUSIONS: Personalized ctDNA detection was effective and stable for high-risk EC. CtDNA tracking in post-operative plasma is valuable for predicting tumor recurrence.
BACKGROUND: Currently, there is no reliable blood-based marker to track tumor recurrence in endometrial cancer (EC) patients. Liquid biopsies, specifically, circulating tumor DNA (ctDNA) analysis emerged as a way to monitor tumor metastasis. The objective of this study was to examine the feasibility of ctDNA in recurrence surveillance and prognostic evaluation of high-risk EC. METHODS:Tumor tissues from nine high-risk EC patients were collected during primary surgery and tumor DNA was subjected to next generation sequencing to obtain the initial mutation spectrum using a 78 cancer-associated gene panel. Baseline and serial post-operative plasma samples were collected and droplet digital PCR (ddPCR) assays for patient-specific mutations were developed to track the mutations in the ctDNA in serial plasma samples. Log-rank test was used to assess the association between detection of ctDNA before or after surgery and disease-free survival. RESULTS: Somatic mutations were identified in all of the cases. The most frequent mutated genes were PTEN, FAT4, ARID1A, TP53, ZFHX3, ATM, and FBXW7. For each patient, personalized ddPCR assays were designed for one-to-three high-frequent mutations. DdPCR analysis and tumor panel sequencing had a high level of agreement in the assessment of the mutant allele fractions in baseline tumor tissue DNA. CtDNA was detected in 67% (6 of 9) of baseline plasma samples, which was not predictive of disease-free survival (DFS). CtDNA was detected in serial post-operative plasma samples (ctDNA tracking) of 44% (4 of 9) of the patients, which predicted tumor relapse. The DFS was a median of 9 months (ctDNA detected) versus median DFS undefined (ctDNA not detected), with a hazard ratio of 17.43 (95% CI, 1.616-188.3). The sensitivity of post-operative ctDNA detection in estimating tumor relapse was 100% and specificity was 83.3%, which was superior to CA125 or HE4. CONCLUSIONS: Personalized ctDNA detection was effective and stable for high-risk EC. CtDNA tracking in post-operative plasma is valuable for predicting tumor recurrence.
Entities:
Keywords:
Circulating tumor DNA; High-risk; Recurrence; endometrial cancer
Authors: M Agostini; M V Enzo; C Bedin; V Belardinelli; E Goldin; P Del Bianco; E Maschietto; E D'Angelo; Leo Izzi; A Saccani; G Zavagno; D Nitti Journal: Cancer Biomark Date: 2012 Impact factor: 4.388
Authors: Muhammed Murtaza; Sarah-Jane Dawson; Dana W Y Tsui; Davina Gale; Tim Forshew; Anna M Piskorz; Christine Parkinson; Suet-Feung Chin; Zoya Kingsbury; Alvin S C Wong; Francesco Marass; Sean Humphray; James Hadfield; David Bentley; Tan Min Chin; James D Brenton; Carlos Caldas; Nitzan Rosenfeld Journal: Nature Date: 2013-04-07 Impact factor: 49.962
Authors: Elena Pereira; Olga Camacho-Vanegas; Sanya Anand; Robert Sebra; Sandra Catalina Camacho; Leopold Garnar-Wortzel; Navya Nair; Erin Moshier; Melissa Wooten; Andrew Uzilov; Rong Chen; Monica Prasad-Hayes; Konstantin Zakashansky; Ann Marie Beddoe; Eric Schadt; Peter Dottino; John A Martignetti Journal: PLoS One Date: 2015-12-30 Impact factor: 3.240
Authors: Ana M Bolivar; Rajyalakshmi Luthra; Meenakshi Mehrotra; Wei Chen; Bedia A Barkoh; Peter Hu; Wei Zhang; Russell R Broaddus Journal: Mod Pathol Date: 2018-10-12 Impact factor: 7.842
Authors: Joshua D Cohen; Lu Li; Yuxuan Wang; Christopher Thoburn; Bahman Afsari; Ludmila Danilova; Christopher Douville; Ammar A Javed; Fay Wong; Austin Mattox; Ralph H Hruban; Christopher L Wolfgang; Michael G Goggins; Marco Dal Molin; Tian-Li Wang; Richard Roden; Alison P Klein; Janine Ptak; Lisa Dobbyn; Joy Schaefer; Natalie Silliman; Maria Popoli; Joshua T Vogelstein; James D Browne; Robert E Schoen; Randall E Brand; Jeanne Tie; Peter Gibbs; Hui-Li Wong; Aaron S Mansfield; Jin Jen; Samir M Hanash; Massimo Falconi; Peter J Allen; Shibin Zhou; Chetan Bettegowda; Luis A Diaz; Cristian Tomasetti; Kenneth W Kinzler; Bert Vogelstein; Anne Marie Lennon; Nickolas Papadopoulos Journal: Science Date: 2018-01-18 Impact factor: 47.728
Authors: Carlos Casas-Arozamena; Alexandra Cortegoso; Raquel Piñeiro-Perez; Alicia Abalo; Efigenia Arias; Victoria Sampayo; Ana Vilar; Marta Bouso; Eva Diaz; Gema Moreno-Bueno; Rafael López-López; Laura Muinelo-Romay; Miguel Abal; Juan Cueva Journal: Int J Mol Sci Date: 2022-08-01 Impact factor: 6.208